Oncolytic viruses: Natural Born KillersAmgen’s Imlygic was approved last year – a move that finally added oncolytic viruses (OVs) to the healthcare toolkit. Although the treatment’s scope of application as a stand-alone therapy is limited, … more ➔
Surviving the turmoil on capital marketsEarly January saw a few indicators that stock markets might deliver some solid biotech results in 2016, even if it wasn’t destined to be a hallmark year for the industry. But then, in the weeks that … more ➔
